Dupixent, the flagship drug of French pharmaceutical giant Sanofi, is undergoing approval in the European Union for a new indication, inflammation of the esophagus, the group announced on Friday. A European Medicines Agency (EMA) committee “has issued a favorable opinion and recommended the approval of Dupixent – dupilumab – in the European Union for the treatment of eosinophilic oesophagitis in adults and adolescent children,” Sanofi said. in a note.
After this opinion from the EMA, it is up to the European Commission to ratify this authorization, which generally constitutes a formality in the following weeks.
Eosinophilic esophagitis is a chronic disease that causes inflammation of the esophagus due to immune dysfunction. It manifests itself with difficulty swallowing and gastric reflux. Dupixent had already been approved for this disease in the United States.
READ ALSO
Sanofi: Brussels approves the extension of the marketing authorization for Dupixent
A flagship drug from the Sanofi group
More generally, Dupixent is Sanofi’s flagship drug, already approved for a wide range of pathologies such as asthma or eczema. It brings several billion euros in turnover for the group, of which it represents a fifth of turnover.
Despite this announcement, Sanofi shares lost more than 1.5% on Friday against a general backdrop of a decline in the Paris Stock Exchange.
READ ALSO
Health: Sanofi’s childhood asthma treatment, Dupixent, approved by the European Commission
Get our latest news
Every morning, the information to remember about financial markets.
